< >

HyperAcute Immunotherapy

NewLink Genetics has multiple HyperAcute immunotherapies currently under development in a variety of tumors

Phase 3 Trial in Pancreatic Cancer

Now enrolling patients with borderline resectable or locally advanced unresectable pancreatic cancer

Phase 2b/3 Trial in Lung Cancer

Now enrolling patients with progressive or relapsed non-small cell lung cancer (NSCLC)

Investor Relations

Keep up with the latest news and presentations
NewLink Genetics' IMPRESS Phase 3 Pancreatic Cancer Trial with Algenpantucel-L to Continue Following Second Interim Analysis
May 11, 2015

NewLink Genetics Corporation Provides Operational Update and Reports First Quarter 2015 Financial Results
May 05, 2015

ANNOUNCEMENTS